We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
Read MoreHide Full Article
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a downswing of 0.58%, while the tech-heavy Nasdaq appreciated by 0.28%.
Shares of the drugmaker have appreciated by 0.97% over the course of the past month, outperforming the Medical sector's loss of 0.01%, and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on February 4, 2026. The company's earnings per share (EPS) are projected to be $7.3, reflecting a 37.22% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $18.21 billion, up 34.58% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $23.83 per share and a revenue of $63.76 billion, signifying shifts of +83.45% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Eli Lilly is presently trading at a Forward P/E ratio of 32.52. This indicates a premium in contrast to its industry's Forward P/E of 15.92.
Meanwhile, LLY's PEG ratio is currently 0.82. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.66.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.
Zacks' 7 Best Strong Buy Stocks (New Research Report)
Valued at $99, click below to receive our just-released report
predicting the 7 stocks that will soar highest in the coming month.
View the Zacks #1 Rank List
Image: Bigstock
Eli Lilly (LLY) Stock Sinks As Market Gains: What You Should Know
In the latest trading session, Eli Lilly (LLY - Free Report) closed at $1,064.29, marking a -2.12% move from the previous day. This change lagged the S&P 500's 0.03% gain on the day. Elsewhere, the Dow saw a downswing of 0.58%, while the tech-heavy Nasdaq appreciated by 0.28%.
Shares of the drugmaker have appreciated by 0.97% over the course of the past month, outperforming the Medical sector's loss of 0.01%, and the S&P 500's gain of 0.6%.
Analysts and investors alike will be keeping a close eye on the performance of Eli Lilly in its upcoming earnings disclosure. The company's earnings report is set to go public on February 4, 2026. The company's earnings per share (EPS) are projected to be $7.3, reflecting a 37.22% increase from the same quarter last year. Our most recent consensus estimate is calling for quarterly revenue of $18.21 billion, up 34.58% from the year-ago period.
For the annual period, the Zacks Consensus Estimates anticipate earnings of $23.83 per share and a revenue of $63.76 billion, signifying shifts of +83.45% and 0%, respectively, from the last year.
Investors should also pay attention to any latest changes in analyst estimates for Eli Lilly. These revisions help to show the ever-changing nature of near-term business trends. As a result, upbeat changes in estimates indicate analysts' favorable outlook on the business health and profitability.
Our research shows that these estimate changes are directly correlated with near-term stock prices. To benefit from this, we have developed the Zacks Rank, a proprietary model which takes these estimate changes into account and provides an actionable rating system.
The Zacks Rank system, running from #1 (Strong Buy) to #5 (Strong Sell), holds an admirable track record of superior performance, independently audited, with #1 stocks contributing an average annual return of +25% since 1988. Over the past month, the Zacks Consensus EPS estimate has moved 0.07% higher. Currently, Eli Lilly is carrying a Zacks Rank of #3 (Hold).
Looking at valuation, Eli Lilly is presently trading at a Forward P/E ratio of 32.52. This indicates a premium in contrast to its industry's Forward P/E of 15.92.
Meanwhile, LLY's PEG ratio is currently 0.82. The PEG ratio is akin to the commonly utilized P/E ratio, but this measure also incorporates the company's anticipated earnings growth rate. As of the close of trade yesterday, the Large Cap Pharmaceuticals industry held an average PEG ratio of 1.66.
The Large Cap Pharmaceuticals industry is part of the Medical sector. This industry currently has a Zacks Industry Rank of 178, which puts it in the bottom 28% of all 250+ industries.
The Zacks Industry Rank gauges the strength of our individual industry groups by measuring the average Zacks Rank of the individual stocks within the groups. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.
Keep in mind to rely on Zacks.com to watch all these stock-impacting metrics, and more, in the succeeding trading sessions.